Session 3G: Treating Heart Failure by Inhibiting PLCB-1 in Rat Ventricular Cardiomyocytes

Session Number

Session 3G: 4th Presentation

Advisor(s)

J. Andrew Wasserstrom, Northwestern University

Location

Room A117

Start Date

28-4-2017 1:15 PM

End Date

28-4-2017 2:30 PM

Abstract

One of the most prevalent chronic heart diseases in the United States, heart failure is the process wherein heart muscles slowly function worse until the heart fails. Many believe heart failure is caused by the loss of the T-tubule structures which are attacked as a result of the activation of PLCB-1. We are looking to find a compound which will prevent the activation of PLCB-1. We used auto TT analysis in order to examine the effectiveness of Compound 4 (C4) in cardiomyocytes treated with C4. We used a confocal microscope to image treated and untreated cells to see T-tubule structural integrity levels. However, the results indicate that C4 requires further testing since it does not seem to produce a sensible dose-response curve.

Share

COinS
 
Apr 28th, 1:15 PM Apr 28th, 2:30 PM

Session 3G: Treating Heart Failure by Inhibiting PLCB-1 in Rat Ventricular Cardiomyocytes

Room A117

One of the most prevalent chronic heart diseases in the United States, heart failure is the process wherein heart muscles slowly function worse until the heart fails. Many believe heart failure is caused by the loss of the T-tubule structures which are attacked as a result of the activation of PLCB-1. We are looking to find a compound which will prevent the activation of PLCB-1. We used auto TT analysis in order to examine the effectiveness of Compound 4 (C4) in cardiomyocytes treated with C4. We used a confocal microscope to image treated and untreated cells to see T-tubule structural integrity levels. However, the results indicate that C4 requires further testing since it does not seem to produce a sensible dose-response curve.